This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
Information provided by:
Asociación para Evitar la Ceguera en México Identifier:
First received: January 3, 2007
Last updated: NA
Last verified: June 2006
History: No changes posted

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.

The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Condition Intervention Phase
Central Serous Chorioretinopathy Drug: Intravitreal injection of Bevacizumab Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Study Start Date: April 2006
Estimated Study Completion Date: August 2006

Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria

  • Any visual acuity.
  • Central serous chorioretinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00418431

Contact: Mitzy E Torres Soriano, MD 525510841400 ext 1172
Contact: Hugo Quiroz-Mercado, MD 525510841400 ext 1171

Asociacion para Evitar la Ceguera en Mexico Recruiting
Mexico DF, DF, Mexico, 04030
Contact: Mitzy E Torres Soriano, MD    5255510841400 ext 1171   
Sub-Investigator: Maura Abraham, MD         
Sub-Investigator: Orlando Ustariz, MD         
Sub-Investigator: Gerardo Garcia Aguirre         
Sub-Investigator: Veronica Kon-Jara, MD         
Sub-Investigator: Hugo Quiroz-Mercado, MD         
Sub-Investigator: Jose L Guerrero, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Mitzy E Torres Soriano, MD APEC
  More Information Identifier: NCT00418431     History of Changes
Other Study ID Numbers: APEC-0016
Study First Received: January 3, 2007
Last Updated: January 3, 2007

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 18, 2017